Price movement over the last 24 hours
Agilent Technologies Inc vs Five9 Inc — how do they compare? Agilent Technologies Inc trades at $128.7 (market cap $37.04B), while Five9 Inc trades at $23.99 (market cap $1.91B). The key difference: Agilent Technologies Inc is far larger — about 19.4× Five9 Inc's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Five9 Inc pays none. Which is the better fit depends on your goals.
| A | FIVN | |
|---|---|---|
Market Cap | $37.04B | $1.91B |
Sector | Health | Technology |
52-Week High | $157.20 | $29.16 |
52-Week Low | $110.24 | $13.61 |
Enterprise Value | $38.59B | $1.99B |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Five9 (FIVN) trades at $24.99, up 6.59% today, showing strong momentum after consistently beating earnings estimates. The stock maintains bullish technical signals with moving averages supporting upward trends, though RSI levels indicate potential overbought conditions. Revenue growth has accelerated from $779M in 2022 to $1.15B in 2025, with the company achieving profitability for the first time in 2025 with $39M net income. Recent leadership appointments and AI product launches signal continued innovation in the CX platform space.
The outlook remains positive with 61% analyst buy ratings and a $27 consensus target offering 8% upside. Key catalysts include sustained revenue growth and margin expansion, while risks involve ongoing fiduciary investigations and competitive pressures in the cloud contact center market. The stock's premium valuation (P/E 37.1) requires continued execution to justify current levels.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →